目的 探討腎炎康復(fù)片聯(lián)合恩格列凈片治療糖尿病腎病的臨床效果。方法 選取2022年7月—2023年11月天津市天津醫(yī)院門(mén)診收治的70例糖尿病腎病患者，用隨機(jī)表法將患者分為對(duì)照組和治療組，各35例。對(duì)照組空腹口服恩格列凈片，10 mg/次，1 次/d。治療組在對(duì)照組的基礎(chǔ)上口服腎炎康復(fù)片，5片/次，3次/d。兩組連續(xù)治療12周。比較兩組的臨床療效、糖代謝指標(biāo)、腎功能指標(biāo)和血清炎癥指標(biāo)。結(jié)果 治療后，對(duì)照組總有效率為71.42%，治療組的總有效率為88.57%，組間比較差異有統(tǒng)計(jì)學(xué)意義（P＜0.05）。治療后，兩組的空腹血糖（FPG）、糖化血紅蛋白（HbA1c）均顯著降低（P＜0.05），治療后，兩組FPG、HbA1c組間比較差異無(wú)統(tǒng)計(jì)學(xué)意義。治療后，兩組尿素氮（BUN）、血肌酐（Scr）、尿微量白蛋白/肌酐比值（UACR）均較前下降（P＜0.05），治療組BUN、Scr、UACR比對(duì)照組更低（P＜0.05）。治療后，兩組血清轉(zhuǎn)化生長(zhǎng)因子（TGF）-β1、腫瘤壞死因子（TNF）-α水平均較前下降（P＜0.05），治療組患者血清TGF-β1、TNF-α水平比對(duì)照組更低（P＜0.05）。結(jié)論 腎炎康復(fù)片聯(lián)合恩格列凈片治療糖尿病腎病提高了臨床療效，可改善其血糖水平，發(fā)揮腎臟保護(hù)作用，減輕患者的炎癥反應(yīng)。

Objective To explore the clinical effect of Shenyan Kangfu Tablets combined with Empagliflozin Tablets in treatment of diabetic nephropathy. Methods Patients (70 cases) with diabetic nephropathy admitted to the outpatient department of Tianjin Hospital from July 2022 to November 2023 were selected and divided into control group and treatment group by random table method, with 35 cases in each group. Patients in control group were po Empagliflozin Tablets on an empty stomach, 10 mg/time, once daily. Patients in the treatment group were po Shenyan Kangfu Tablets on the basis of control group, 5 tablets/time, 3 times daily. Both groups were treated for 12 weeks. The clinical efficacy, glucose metabolism index, renal function index, and serum inflammation index were compared between two groups. Results After treatment, the total effective rates of the control group and the treatment group were 71.42% and 88.57%, and the difference between two groups was statistically significant (P < 0.05). After treatment, FPG and HbA1c in two groups were significantly decreased (P < 0.05), and there was no significant difference in FPG and HbA1c between two groups. After treatment, BUN, Scr, and UACR in two groups were lower than before (P < 0.05), and BUN, Scr, and UACR in the treatment group were lower than those in the control group (P < 0.05). After treatment, the serum levels of TGF-β1 and TNF-α were decreased in two groups (P < 0.05), and the serum levels of TGF-β1 and TNF-α in the treatment group were lower than those in the control group (P < 0.05). Conclusion Shenyan Kangfu Tablets combined with Empagliflozin Tablets in treatment of diabetic nephropathy can improve the clinical effect, improve the level of blood sugar, protect kidney, and reduce the inflammatory response.

R983